Literature DB >> 28589086

Lymph Node Metastases in Papillary and Medullary Thyroid Carcinoma Are Independent of Intratumoral Lymphatic Vessel Density.

Filipe Pereira1, Sofia S Pereira1,2, Marta Mesquita3, Tiago Morais1, Madalena M Costa1, Pedro Quelhas2,4, Carlos Lopes5,6, Mariana P Monteiro1, Valeriano Leite7,8.   

Abstract

BACKGROUND: Blood and lymph vessel invasion are well-recognized markers of tumor aggressiveness, as these are the routes that lead to metastases. Thyroid tumors, depending on the histological variant, tend to have distinctive biological behaviors and use different vascular routes to metastasize, yet the mechanisms underlying the metastatic process are still poorly understood.
OBJECTIVES: The aim of this study was to assess how the lymph vessel density (LVD) in different histological types of thyroid tumors, and in their surrounding tissue, correlate with the presence of lymph node metastases (LNM) and tumor pathological features.
METHODS: Lymph vessels of papillary thyroid carcinomas (PTC), of the classical (CVPTC, n = 50) and follicular variants (FVPTC, n = 18), and medullary thyroid carcinomas (MTC, n = 34) were immunohistochemically stained against antigen D2-40. The stained area was quantified using a computerized morphometric analysis tool and correlated with the tumor pathological characteristics.
RESULTS: LVD within all analyzed thyroid tumor subtypes was significantly lower than in the surrounding thyroid tissues (p < 0.001). Despite intratumoral LVD being significantly higher in CVPTC than in FVPTC, and peritumoral LVD being significantly higher in MTC than in PTC (p < 0.05), no correlations were found between LVD (either intratumoral or peritumoral) and the presence of lymph node metastasis.
CONCLUSIONS: As no LVD differences were found amongst thyroid tumors with or without LNM, dissemination is more likely to depend on the tumor ability to invade the abundant lymph vessel network of the surrounding thyroid tissue than on the ability of the tumor to promote de novo lymphangiogenesis.

Entities:  

Keywords:  Lymph vessels; Medullary carcinoma; Metastasis; Papillary carcinoma; Thyroid

Year:  2017        PMID: 28589086      PMCID: PMC5422756          DOI: 10.1159/000457794

Source DB:  PubMed          Journal:  Eur Thyroid J        ISSN: 2235-0640


  22 in total

Review 1.  LYVE-1, the lymphatic system and tumor lymphangiogenesis.

Authors:  D G Jackson; R Prevo; S Clasper; S Banerji
Journal:  Trends Immunol       Date:  2001-06       Impact factor: 16.687

2.  High expression of spindle assembly checkpoint proteins CDC20 and MAD2 is associated with poor prognosis in urothelial bladder cancer.

Authors:  Jung-Woo Choi; Younghye Kim; Ju-Han Lee; Young-Sik Kim
Journal:  Virchows Arch       Date:  2013-08-31       Impact factor: 4.064

3.  Angiogenesis and lymphangiogenesis in thyroid proliferative lesions: relationship to type and tumour behaviour.

Authors:  N Garcia de la Torre; I Buley; J A H Wass; H E Turner
Journal:  Endocr Relat Cancer       Date:  2006-09       Impact factor: 5.678

4.  Absence of functional lymphatics within a murine sarcoma: a molecular and functional evaluation.

Authors:  A J Leu; D A Berk; A Lymboussaki; K Alitalo; R K Jain
Journal:  Cancer Res       Date:  2000-08-15       Impact factor: 12.701

5.  Prognostic utility of quantitative image analysis of microvascular density in prostate cancer.

Authors:  Ugur Ozerdem; Eva M Wojcik; Xiuzhen Duan; Çağatay Erşahin; Güliz A Barkan
Journal:  Pathol Int       Date:  2013-05       Impact factor: 2.534

6.  Expression of vascular endothelial growth factor-C in benign and malignant thyroid tumors.

Authors:  Chung J Hung; David G Ginzinger; Raza Zarnegar; Hajime Kanauchi; Mariwil G Wong; Electron Kebebew; Orlo H Clark; Quan-Yang Duh
Journal:  J Clin Endocrinol Metab       Date:  2003-08       Impact factor: 5.958

Review 7.  Prognostic factors and therapeutic strategies for differentiated carcinomas of the thyroid.

Authors:  Yasuhiro Ito; Akira Miyauchi
Journal:  Endocr J       Date:  2008-08-13       Impact factor: 2.349

Review 8.  Involvement of level IIb lymph node metastasis and dissection in thyroid cancer.

Authors:  Yusuf Vayisoglu; Cengiz Ozcan
Journal:  Gland Surg       Date:  2013-11

9.  Genetic alterations in poorly differentiated and undifferentiated thyroid carcinomas.

Authors:  Paula Soares; Jorge Lima; Ana Preto; Patricia Castro; João Vinagre; Ricardo Celestino; Joana P Couto; Hugo Prazeres; Catarina Eloy; Valdemar Máximo; M Sobrinho-Simões
Journal:  Curr Genomics       Date:  2011-12       Impact factor: 2.236

10.  The emerging role of the molecular marker p27 in the differential diagnosis of adrenocortical tumors.

Authors:  Sofia S Pereira; Tiago Morais; Madalena M Costa; Mariana P Monteiro; Duarte Pignatelli
Journal:  Endocr Connect       Date:  2013-08-28       Impact factor: 3.335

View more
  4 in total

1.  Angiogenesis and Lymphangiogenesis in the Adrenocortical Tumors.

Authors:  Sofia S Pereira; Madalena M Costa; Susana G Guerreiro; Mariana P Monteiro; Duarte Pignatelli
Journal:  Pathol Oncol Res       Date:  2017-07-10       Impact factor: 3.201

Review 2.  Is Encapsulated Medullary Thyroid Carcinoma Associated With a Better Prognosis? A Case Series and a Review of the Literature.

Authors:  Andrea Contarino; Alessia Dolci; Marco Maggioni; Francesca Maria Porta; Gianluca Lopez; Uberta Verga; Francesca Marta Elli; Elisabetta Francesca Iofrida; Gianmaria Cantoni; Giovanna Mantovani; Maura Arosio
Journal:  Front Endocrinol (Lausanne)       Date:  2022-04-27       Impact factor: 6.055

3.  Sentinel Lymph Node Biopsy in Thyroid Cancer.

Authors:  Max B Albers; Erik Nordenström; Johan Wohlfahrt; Anders Bergenfelz; Martin Almquist
Journal:  World J Surg       Date:  2020-01       Impact factor: 3.352

4.  Lymphatic vessel density as a prognostic indicator in Asian NSCLC patients: a meta-analysis.

Authors:  Shuanglan Xu; Jiao Yang; Shuangyan Xu; Yun Zhu; Chunfang Zhang; Liqiong Liu; Hao Liu; Yunlong Dong; Zhaowei Teng; Xiqian Xing
Journal:  BMC Pulm Med       Date:  2018-08-06       Impact factor: 3.317

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.